Clinical trialsCompany release

Context's CTIM-76 posts 22% confirmed response in platinum-resistant ovarian cancer

🇺🇸 Context Therapeutics Inc. (CNTX) · Tue 10 Nov 2026

Updated Phase 1 data for the Claudin 6 x CD3 T cell engager show a 5.6-month median PFS, with liver enzyme elevations emerging as a dose-related safety issue.

Context Therapeutics reported updated Phase 1 data for CTIM-76, a Claudin 6 x CD3 T cell engager, on 10 November 2026 alongside its third-quarter results. The data come from heavily pretreated patients with platinum-resistant ovarian cancer.

At active dose levels given weekly, the confirmed objective response rate was 22% and median progression-free survival was 5.6 months, according to the company.

On safety, cytokine release syndrome was limited to Grade 1-2. Grade 3 or higher liver enzyme elevations were dose-related. Escalation of every-three-week dosing is under way and has reached 420 µg.

The US Food and Drug Administration has granted CTIM-76 Fast Track designation, a status intended to speed development of products for serious conditions with unmet need. A Phase 1b study is planned for the first quarter of 2027. Context reported cash of $34.4 million, which it expects to fund operations until early in the fourth quarter of 2027.

What it means for your team

  • Dose-related Grade 3 or higher liver enzyme elevations are a safety signal to watch as every-three-week dosing is escalated, and may shape dose selection for Phase 1b.
  • Fast Track designation offers more frequent FDA interaction, which could matter for the regulatory path of the Phase 1b programme.
  • The cash runway to early Q4 2027 covers the planned Phase 1b start but is a limited window for a company at this stage.

Company's press release (SEC filing): Context Therapeutics Inc. ↗

Article written by VigiEye from the official source (Context Therapeutics Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →